FDA Approved Veterinary Drugs Compiled and Produced by M

Total Page:16

File Type:pdf, Size:1020Kb

FDA Approved Veterinary Drugs Compiled and Produced by M FDA Approved Veterinary Drugs Compiled and Produced by M. Haziq Qureshi and Kevin A. Scott of the Njarðarson Group (The University of Arizona) Monensin Laidlomycin Propionate Maduramicin Semduramicin Narasin Salinomycin Lasalocid Trichlorfon Dichlorvos Coumaphos Haloxon Phosmet Cythioate Famphur Fenthion Emodepside Eprinomectin Selamectin Doramectin Milbemycin Oxime Moxidectin Ivermectin Spinosad Nicarbazin Imidocarb Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Robenidine Amitraz Thiacetarsamide Melarsomine Fluralaner Lotilaner Afoxolaner Sarolaner Levamisole Butamisole Diclazuril Ponazuril Morantel Pyrantel Epsiprantel Praziquantel Bunamidine Lufenuron Halofuginone Carnidazole Butyl Chloride Nitenpyram Clorsulon Dinitolmide Imidacloprid Tramisol (racemic) Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Dithiazanine Iodide Nequinate Decoquinate Clopidol Amprolium Thenium Closylate Xylenes Toluene Febantel Fenbendazole Oxibendazole Tioxidazole Oxfendazole Mebendazole Albendazole Piperazine Diethylcarbamazine Cefadroxil Ceftriaxone Ceftiofur Cefovecin Cefpodoxime Proxetil Cephalexin Cephapirin Cloxacillin Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-parasitic Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Dicloxacillin Hetacillin Amoxicillin Ampicillin Penicillin G Penicillin V Ticarcillin Chlortetracycline Doxycycline Tetracycline Oxytetracycline Danofloxacin Enrofloxacin Pradofloxacin Difloxacin Orbifloxacin Marbofloxacin Sulfaquinoxaline Sulfaethoxypyridazine Sulfachloropyridazine Sulfaclozine Sulfachlorpyrazine Sulfabromomethazine Sulfamethizole Sulfafurazole Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Sulfadiazine Sulfamerazine Sulfamethazine Sulfadimethoxine Dihydrostreptomycin Apramycin Biodacyn Amikacin Kanamycin A Gentamicin C-2 Streptomycin Neomycin B Novobiocin Mupirocin Spectinomycin Tiamulin Efrotomycin Lincomycin Clindamycin Pirlimycin Gamithromycin Tulathromycin Tildipirosin Oleandromycin Tylosin Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Tylvalosin Tilmicosin Erythromycin Bacitracin Polymyxin B Bambermycin Avilamycin Moenomycin A Virginiamycin Sulfomycin I Amphomycin Thiostrepton Methenamine Hexamidine Chlorhexidine Carbadox Dichlorophen Florfenicol Chloramphenicol Ormetoprim Pyrimethamine Trimethoprim Furazolidone Nitrofurantoin Nitrofurazone Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Anti-bacterial Posaconazole Itraconazole Tolnaftate Clioquinol Nystatin Miconazole Clotrimazole Thiabendazole Terbinafine Selenium Disulfide Fenprostalene Fluprostenol Cloprostenol Luprostiol Dinoprost Levothyroxine Liothyronine Methimazole Phenylpropanolamine Pseudoephedrine Selegiline Clenbuterol Salbutamol Phenylephrine Triflupromazine Anti-fungal Anti-fungal Anti-fungal Anti-fungal Anti-fungal Anti-fungal Anti-fungal Anti-fungal Anti-fungal Anti-fungal Reproductive Reproductive Reproductive Reproductive Reproductive Endocrine Endocrine Endocrine Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Aminopromazine Promazine Acepromazine Etymemazine Propionylpromazine Trimeprazine Prochlorperazine Phenothiazine Diazepam Zolazepam Imepitoin Fluoxetine Doxapram Droperidol Carbamazepine Domperidone Pergolide Clomipramine Tripelennamine Pyrilamine Brompheniramine Chlorpheniramine Glycopyrrolate Methscopolamine Butylscopolamine Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Atropine Chlorphenesin Carbamate Caramiphen Isopropamide Aminopentamide Mirtazapine Naltrexone Buprenorphine Diprenorphine Nalorphine Butorphanol Pentazocine (racemic) Dextromethorphan Atipamezole Ractopamine Zilpaterol Yohimbine Tolazoline Detomidine Dexmedetomidine Xylazine Romifidine Chloral Hydrate Halothane Isoflurane Medetomidine (rac) Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Sevoflurane Tiletamine Lidocaine Bupivacaine Mepivacaine Procaine Tetracaine Tricaine Benzocaine Propofol Primidone Pentobarbital Thialbarbital Thiopental Thiamylal Embutramide Azaperone Carfentanil Fentanyl Etodolac Naproxen Ketoprofen Carprofen Meclofenamic Acid Flunixin Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System Nervous System NSAID NSAID NSAID NSAID NSAID NSAID Robenacoxib Diclofenac Tepoxalin Deracoxib Firocoxib Metamizole Phenylbutazone Dimethylnortestosterone Boldenone undecylenate Melengestrol acetate Alfaxalone Stanozolol Trilostane Betamethasone Betamethasone Acetate Betamethasone Phosphate Prednisolone Prednisone Methylprednisolone Betamethasone valerate Dexamethasone Flumetasone Hydrocortisone Hydrocortisone aceponate Mometasone furoate NSAID NSAID NSAID NSAID NSAID NSAID NSAID Reproductive Reproductive Reproductive Nervous System Reproductive Endocrine Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Isoflupredone acetate Fluocinolone acetonide Triamcinolone acetonide Desoxycorticosterone pivalate Progesterone Megestrol acetate Norgestomet Testosterone Estriol Estradiol Trenbolone Trenbolone 17b-acetate Altrenogest Zeranol Hydrochlorothiazide Chlorothiazide Trichlormethiazide Meloxicam Furosemide Acetazolamide Telmisartan Pimobendan Enalapril Toceranib Clodronate Anti-inflammatory Anti-inflammatory Anti-inflammatory Anti-inflammatory Reproductive Reproductive Reproductive Reproductive Reproductive Reproductive Reproductive Reproductive Reproductive Reproductive Cardiovascular Cardiovascular Cardiovascular NSAID Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Oncology Oncology Masitinib Rabacfosadine Guaifenesin Lubabegron Fomepizole Dirlotapide Melatonin Maropitant b-aminopropionitrile 2-Mercaptobenzothiazole Oclacitinib Cyclosporin Diatrizoate Alendronate a-Tocopherol Lauromacrogol Poloxalene Polysulfated Hyaluronic acid Pralidoxime Gleptoferron Zinc gluconate Capromorelin Omeprazole Neostigmine Glycosaminoglycan Oncology Oncology Nervous System Alimentary Antidote Alimentary Nervous System Nervous System Skeletomuscular Dermatological Dermatological Immulogical Contrast Agent Skeletomuscular Alimentary Dermatological Alimentary Skeletomuscular Skeletomuscular Antidote Alimentary Alimentary Alimentary Alimentary Neurological Anti-bacterial Anti-parasitic Anti-fungal Reproductive Endocrine Nervous System NSAID Anti-inflammatory Cardiovascular Oncology Alimentary Skeletomuscular Miscellaneous.
Recommended publications
  • Full Text in Pdf Format
    DISEASES OF AQUATIC ORGANISMS Published July 30 Dis Aquat Org Oral pharmacological treatments for parasitic diseases of rainbow trout Oncorhynchus mykiss. 11: Gyrodactylus sp. J. L. Tojo*, M. T. Santamarina Department of Microbiology and Parasitology, Laboratory of Parasitology, Faculty of Pharmacy, Universidad de Santiago de Compostela, E-15706 Santiago de Compostela, Spain ABSTRACT: A total of 24 drugs were evaluated as regards their efficacy for oral treatment of gyro- dactylosis in rainbow trout Oncorhj~nchusmykiss. In preliminary trials, all drugs were supplied to infected fish at 40 g per kg of feed for 10 d. Twenty-two of the drugs tested (aminosidine, amprolium, benznidazole, b~thionol,chloroquine, diethylcarbamazine, flubendazole, levamisole, mebendazole, n~etronidazole,mclosamide, nitroxynil, oxibendazole, parbendazole, piperazine, praziquantel, roni- dazole, secnidazole, tetramisole, thiophanate, toltrazuril and trichlorfon) were ineffective Triclabenda- zole and nitroscanate completely eliminated the infection. Triclabendazole was effective only at the screening dosage (40 g per kg of feed for 10 d), while nitroscanate was effective at dosages as low as 0.6 g per kg of feed for 1 d. KEY WORDS: Gyrodactylosis . Rainbow trout Treatment. Drugs INTRODUCTION to the hooks of the opisthohaptor or to ulceration as a result of feeding by the parasite. The latter is the most The monogenean genus Gyrodactylus is widespread, serious. though some individual species have a restricted distri- Transmission takes place largely as a result of direct bution. Gyrodactyloses affect numerous freshwater contact between live fishes, though other pathways species including salmonids, cyprinids and ornamen- (contact between a live fish and a dead fish, or with tal fishes, as well as marine fishes including gadids, free-living parasites present in the substrate, or with pleuronectids and gobiids.
    [Show full text]
  • Bulletin Leading the Fight Against Heartworm Disease
    BULLETIN LEADING THE FIGHT AGAINST HEARTWORM DISEASE SEPTEMBER HEARTWORM 2017 Q&A VOLUME 44 No. 3 Heartworm History: In What Year Was Heartworm First INSIDE THIS ISSUE Treated? Page 4 From the President Page 8 Research Update Abstracts from the Literature Page 14 Heartworm Hotline: Role of Heat Treatment in Diagnostics Page 19 NEW! Best Practices: Minimizing Heartworm Transmission in Relocated Dogs uestions from members, prac- published in the 1998 AHS Symposium 1 titioners, technicians, and the Proceedings. Dr. Roncalli wrote, “The Page 21 Qgeneral public are often submit- first trial to assess the efficacy of a Welcome Our New AHS ted to the American Heartworm Society microfilaricide (natrium antimonyl tar- Student Liaisons (AHS) via our website. Two of our AHS trate) was conducted some 70 years Board members, Dr. John W.McCall and ago (1927) in Japan by S. Itagaki and R. Page 25 Dr. Tom Nelson, provided the resources Makino.2 Fuadin (stibophen), a trivalent In the News: Surgeons to answer this question: In What Year antimony compound, was tested, intra- Remove a Heartworm from Was Heartworm First Treated? venously, as a microfilaricide by Popescu the Femoral Artery of a Cat The first efforts to treat canine heart- in 1933 in Romania and by W.H. Wright worm disease date back to the 1920s. Dr. and P.C. Underwood in 1934 in the USA. Page 26 Nelson referenced a review article by Dr. In 1949, I.C. Mark evaluated its use Quarterly Update Raffaele Roncalli, “Tracing the History of intraperitoneally.” What’s New From AHS? Heartworms: A 400 Year Perspective,” Continues on page 7 American Heartworm Society / PO Box 8266, Wilmington, DE 19803-8266 Become an American Heartworm Society www.heartwormsociety.org / [email protected] fan on Facebook! Follow us on Twitter! OUR GENEROUS SPONSORS PLATINUM LEVEL PO Box 8266 Wilmington, DE 19803-8266 [email protected] www.heartwormsociety.org Mission Statement The mission of the American Heartworm Society is to lead the vet- erinary profession and the public in the understanding of heartworm disease.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Review Article
    REVIEW ARTICLE COLLAGEN METABOLISM COLLAGEN METABOLISM Types of Collagen 228 Structure of Collagen Molecules 230 Synthesis and Processing of Procollagen Polypeptides 232 Transcription and Translation 233 Posttranslational Modifications 233 Extracellular Processing of Procollagen and Collagen Fibrillogenesis 240 Functions of Collagen in Connective rissue 243 Collagen Degradation 245 Regulation of the Metabolism of Collagen 246 Heritable Diseases of Collagen 247 Recessive Dermatosparaxis 248 Recessive Forms of EDS 251 EDS VI 251 EDS VII 252 EDS V 252 Lysyl Oxidase Deficiency in the Mouse 253 X-Linked Cutis Laxa 253 Menke's Kinky Hair Syndrome 253 Homocystinuria 254 EDS IV 254 Dominant Forms of EDS 254 Dominant Collagen Packing Defect I 255 Dominant and Recessive Forms of Osteogenesis Imperfecta 258 Dominant and Recessive Forms of Cutis Laxa 258 The Marfan Syndrome 259 Acquired Diseases and Repair Processes Affecting Collagen 259 Acquired Changes in the Types of Collagen Synthesis 260 Acquired Changes in Amounts of Collagen Synthesized 263 Acquired Changes in Hydroxylation of Proline and Lysine 264 Acquired Changes in Collagen Cross-Links 265 Acquired Defects in Collagen Degradation 267 Conclusion 267 Bibliography 267 Collagen Metabolism A Comparison of Diseases of Collagen and Diseases Affecting Collagen Ronald R. Minor, VMD, PhD COLLAGEN CONSTITUTES approximately one third of the body's total protein, and changes in synthesis and/or degradation of colla- gen occur in nearly every disease process. There are also a number of newly described specific diseases of collagen in both man and domestic animals. Thus, an understanding of the synthesis, deposition, and turnover of collagen is important for the pathologist, the clinician, and the basic scientist alike.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • An Evaluation of Eprinomectin Extended-Release Injectable (Longrange®) on the Performance of Yearling Cattle on Pasture in Western Canada
    PEER REVIEWED © Copyright American Association American© Copyright ofBovine Practitioners; open access distribution. An evaluation of eprinomectin extended-release injectable (LongRange®) on the performance of yearling cattle on pasture in western Canada Ryan D. Rademacher, BSc, DVM; Eric J. Behlke, BSc, MSc, PhD, DVM; Sandi L. Parr, BSc, MSc, PhD; Sherry J. Hannon, DVM, MVetSc, PhD; Christina M. Williams, BSc, MSc; R. Kent Fenton, DVM; G. Kee Jim, DVM; Calvin W. Booker, DVM, MVetSc Feedlot Health Management Services Ltd., PO Box 140, Okotoks, Alberta, Canada T1S 2A2 Corresponding author: Dr. Calvin Booker; Tel: (403) 938-5151; Fax: (403) 938-5175; [email protected] Abstract sous forme injectable a la dose de 0.45 mg/lb (1.0 mg/kg) d'unite de poids corporel (PC) dans la partie lache de la peau During the pre-shipment handling procedures at each devant l'epaule. Les animaux dans le groupe IVER (1524 ani­ of 2 feedlots of origin, mixed-breed beef steers were weighed, maux) ont re<;u a l'allocation une application d'ivermectine sur stratified into weight blocks, and simultaneously randomized le long de la ligne superieure du garrot jusqu’a l’attache de la within weight block to 1 of 2 experimental groups (LONG or queue a la dose de 0.23 mg/lb (0.5 mg/kg) d’unite de PC. Apres IVER) prior to shipment to pasture. Animals in the LONG l’allocation, les animaux des deux groupes experimentaux ont group (1523 animals) received a subcutaneous injection of ete amalgames a l'interieur de chaque bloc de poids et selon le eprinomectin extended-release injectable at a dosage of 0.45 pare d'alimentation d’origine et sont restes dans ces groupes mg/lb (1.0 mg/kg) body weight (BW) in the loose skin in front amalgames pendant toute la duree de l’etude.
    [Show full text]
  • Multi-Residual Quantitative Analytical Method for Antibiotics in Sea Food by LC/MS/MS
    PO-CON1742E Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS ASMS 2017 TP 198 Anant Lohar, Shailendra Rane, Ashutosh Shelar, Shailesh Damale, Rashi Kochhar, Purushottam Sutar, Deepti Bhandarkar, Ajit Datar, Pratap Rasam and Jitendra Kelkar Shimadzu Analytical (India) Pvt. Ltd., 1 A/B, Rushabh Chambers, Makwana Road, Marol, Andheri (E), Mumbai-400059, Maharashtra, India. Multi-residual quantitative analytical method for antibiotics in sea food by LC/MS/MS Introduction Antibiotics are widely used in agriculture as growth LC/MS/MS method has been developed for quantitation of enhancers, disease treatment and control in animal feeding multi-residual antibiotics (Table 1) from sea food sample operations. Concerns for increased antibiotic resistance of using LCMS-8040, a triple quadrupole mass spectrometer microorganisms have prompted research into the from Shimadzu Corporation, Japan. Simultaneous analysis environmental occurrence of these compounds. of multi-residual antibiotics often exhibit peak shape Assessment of the environmental occurrence of antibiotics distortion owing to their different chemical nature. To depends on development of sensitive and selective overcome this, autosampler pre-treatment feature was analytical methods based on new instrumental used [1]. technologies. Table 1. List of antibiotics Sr.No. Name of group Name of compound Number of compounds Flumequine, Oxolinic Acid, Ciprofloxacin, Danofloxacin, Difloxacin.HCl, 1 Fluoroquinolones 8 Enrofloxacin, Sarafloxacin HCl Trihydrate,
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]